MA
CRSP icon

Montag & Associates’s CRISPR Therapeutics CRSP Stock Holding History

Montag & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75
Closed -$3.39K – 931
2023
Q1 		$3.39K Sell
75
-100
-57% -$4.86K ﹤0.01% 842
2022
Q4 		$7.11K Sell
175
-100
-36% -$5.3K ﹤0.01% 780
2022
Q3 		$18K Sell
275
-733
-73% -$53.1K ﹤0.01% 670
2022
Q2 		$61K Sell
1,008
-860
-46% -$50.6K ﹤0.01% 503
2022
Q1 		$117K Sell
1,868
-436
-19% -$27.4K 0.01% 444
2021
Q4 		$175K Sell
2,304
-1,969
-46% -$172K 0.01% 402
2021
Q3 		$478K Buy
4,273
+79
+2% +$9.92K 0.03% 299
2021
Q2 		$679K Buy
4,194
+102
+2% +$12.4K 0.04% 264
2021
Q1 		$499K Sell
4,092
-210
-5% -$31.7K 0.03% 292
2020
Q4 		$659K Buy
4,302
+272
+7% +$32.1K 0.04% 242
2020
Q3 		$337K Buy
+4,030
New +$357K 0.03% 258

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Montag & Associates's CRSP Position: Q2 2023 in Review

Montag & Associates sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 75 shares — an estimated $3.39K sold.

Montag & Associates first reported a position in CRSP in Q3 2020 and held it in 11 quarters. The position peaked at $679K in Q2 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

  • Montag & Associates reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Montag & Associates sold 75 CRISPR Therapeutics shares in Q2 2023, an estimated $3.39K.
  • Montag & Associates first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 11 quarters.
  • Montag & Associates's CRISPR Therapeutics position peaked at $679K in Q2 2021.
  • 418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Montag & Associates's 13F filing for Q2 2023, filed 9 Aug 2023.